Ep203: Sri Kosuri on Small Molecule Correctors of Disease
Jun 16, 2026 - 01:11:43
Radio and PodcastLive Radio & PodcastsScience & Medicine
Ep192: Kate Haviland on Following the Science to Precision Immunology
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
About This Episode
Ep192: Kate Haviland on Following the Science to Precision Immunology is an episode from The Long Run with Luke Timmerman by The Long Run with Luke Timmerman. Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned...
Podcast
This episode belongs to The Long Run with Luke Timmerman.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 8, 2026, 01:26:06 long, audio available.
Related Episodes
Continue listening to more episodes from The Long Run with Luke Timmerman.
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
Jun 2, 2026 - 01:08:12
Ep201: Jeremy Levin on Biotech in the Balance
May 19, 2026 - 01:08:40
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
May 5, 2026 - 01:13:31
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
Apr 21, 2026 - 01:10:08
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Apr 7, 2026 - 01:16:43
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
Mar 31, 2026 - 01:16:57
Ep196: Otello Stampacchia on Europe's Biotech Crisis
Mar 17, 2026 - 01:03:17